Skip to main content

Table 1 Baseline demographics, lipids, lipoproteins, and hs-CRP

From: Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk

  Abdominal Obesitya males (females) TG HDL-C males (females) SB (DBP) FG HOMA-IR
  <40 in (<35in) ≥40 in (≥35in) <150 mg/dL ≥150 mg/dL ≥40 mg/dL (≥50 mg/dL) <40 mg/dL (<50 mg/dL) <130 mmHg (<85 mgHg) ≥130 mmHg (≥85 mmHg) <100 mg/dL ≥100 mg/dL <2.72 2.72 - 4.81 >4.81
  All A (N = 94) All E/S (N = 56) All A (N = 586) All E/S (N = 399) All A (N = 212) All E/S (N = 146) All A (N = 474) All E/S (N = 311) All A (N = 287) All E/S (N = 195) All A (N = 399) All E/S (N = 262) All A (N = 56) All E/S (N = 37) All A (N = 630) All E/S (N = 420) All A (N = 196) All E/S (N = 151) All A (N = 490) All E/S (N = 306) All A (N = 232) All E/S (N = 145) All A (N = 225) All E/S (N = 152) All A (N = 218) All E/S (N = 155)
Mean Age (SD) 59.2 (9.0) 62.4 (7.5) 58.7 (9.7) 59.3 (9.6) 60.2 (9.4) 60.3 (9.2) 58.1 (9.7) 59.3 (9.6) 60.5 (9.5) 60.7 (9.6) 57.5 (9.6) 58.8 (9.3) 53.5 (9.5) 51.6 (11.2) 59.2 (9.5) 60.3 (8.9) 59 (10.2) 58.8 (8.9) 58.7 (9.4) 60 (9.7) 60 (10.3) 60. 9 (8.6) 58.5 (8.7) 59.9 (9.9) 57. 6 (9.7) 58.2 (9.5)
Female, n(%) 24 (25.5) 9 (16.1) 281 (48.0) 180 (45.1) 106 (50.0) 68 (46.6) 201 (42.4) 123 (39.5) 107 (37.3) 66 (33.8) 200 (50.1) 125 (47.7) 31 (55.4) 13 (35.1) 276 (43.8) 178 (42.4) 78 (39.8) 51 (33.8) 229 (46.7) 140 (45.8) 102 (44.0) 57 (39.3) 100 (44.4) 67 (44.1) 100 (45.9) 66 (42.6)
White, n(%) 68 (72.3) 37 (66.1) 443 (75.6) 301 (75.4) 157 (74.1) 106 (72.6) 359 (75.7) 234 (75.2) 231 (80.5) 162 (83.1) 285 (71.4) 178 (67.9) 47 (83.9) 26 (70.3) 469 (74.4) 314 (74.8) 129 (65.8) 99 (65.6) 387 (79.0) 241 (78.8) 166 (71.6) 99 (68.3) 164 (72.9) 113 (74.3) 176 (80.7) 124 (80.0)
Black, n(%) 4 (4.3) 4 (7.1) 41 (7.0) 26 (6.5) 21 (9.9) 17 (11.6) 24 (5.1) 13 (4.2) 13 (4.5) 11 (5.6) 32 (8.0) 19 (7.3) 2 (3.6) 1 (2.7) 43 (6.8) 29 (6.9) 17 (8.7) 9 (6.0) 28 (5.7) 21 (6.9) 11 (4.7) 9 (6.2) 21 (9.3) 10 (6.6) 13 (6.0) 11 (7.1)
Other, n(%) 22 (23.4) 15 (26.8) 102 (17.4) 72 (18.0) 34 (16.0) 23 (15.8) 91 (19.2) 64 (20.6) 43 (15.0) 22 (11.3) 82 (20.6) 65 (24.8) 7 (12.5) 10 (27.0) 118 (18.7) 77 (18.3) 50 (25.5) 43 (28.5) 75 (15.3) 44 (14.4) 55 (23.7) 37 (25.5) 40 (17.8) 29 (19.1) 29 (13.3) 20 (12.9)
CHD n(%) 25 (26.6) 17 (30.4) 104 (17.7) 76 (19.0) 46 (21.7) 30 (20.5) 84 (17.7) 63 (20.3) 47 (16.4) 33 (16.9) 83 (20.8) 60 (22.9) 7 (12.5) 5 (13.5) 123 (19.5) 88 (21.0) 52 (26.5) 32 (21.2) 78 (15.9) 61 (19.9) 45 (19.4) 34 (23.4) 44 (19.6) 30 (19.7) 37 (17.0) 28 (18.1)
With AVD, n(%) 32 (34.0) 21 (37.5) 162 (27.6) 117 (29.3) 65 (30.7) 44 (30.1) 131 (27.6) 94 (30.2) 80 (27.9) 53 (27.2) 116 (29.1) 85 (32.4) 8 (14.3) 8 (21.6) 188 (29.8) 130 (31.0) 75 (38.3) 48 (31.8) 121 (24.7) 90 (29.4) 66 (28.4) 49 (33.8) 68 (30.2) 44 (28.9) 58 (26.6) 43 (27.7)
BMI ≥ 30 kg/m2, n(%) 16 (17.2) 7 (12.5) 387 (66.5) 267 (66.9) 133 (63.0) 89 (61.0) 276 (58.7) 186 (59.8) 164 (57.5) 112 (57.4) 245 (61.9) 163 (62.2) 31 (55.4) 23 (62.2) 378 (60.5) 252 (60.0) 96 (49.0) 80 (53.0) 313 (64.5) 195 (63.7) 91 (39.6) 60 (41.4) 141 (62.7) 102 (67.1) 170 (78.3) 110 (71.0)
Diabetes, n(%) 39 (41.5) 13 (23.2) 339 (57.8) 221 (55.4) 145 (68.4) 96 (65.8) 236 (49.8) 140 (45.0) 159 (55.4) 116 (59.5) 222 (55.6) 120 (45.8) 42 (75.0) 19 (51.4) 339 (53.8) 217 (51.7) 19 (9.7) 16 (10.6) 362 (73.9) 220 (71.9) 89 (38.4) 52 (35.9) 128 (56.9) 80 (52.6) 156 (71.6) 103 (66.5)
Metabolic Syndrome, n(%) 70 (74.5) 41 (73.2) 566 (96.6) 387 (97.0) 180 (85.3) 128 (88.3) 461 (97.3) 301 (96.8) 248 (86.7) 171 (87.7) 393 (98.5) 258 (98.9) 48 (85.7) 34 (91.9) 593 (94.3) 395 (94.3) 168 (85.7) 130 (86.7) 473 (96.7) 299 (97.7) 203 (87.9) 124 (86.1) 214 (95.1) 148 (97.4) 213 (97.7) 152 (98.1)
 TG ≥ 150 mg/dL, n(%) 73 (77.7) 41 (73.2) 397 (67.7) 269 (67.4) 0 0 474 (100) 311 (100) 176 (61.3) 116 (59.5) 298 (74.7) 195 (74.4) 45 (80.4) 32 (86.5) 429 (68.1) 279 (66.4) 160 (81.6) 122 (80.8) 314 (64.1) 189 (61.8) 156 (67.2) 92 (63.4) 160 (71.1) 105 (69.1) 152 (69.7) 109 (70.3)
 Low HDL-C, n(%) 58 (61.7) 36 (64.3) 337 (57.5) 224 (56.1) 101 (47.6) 67 (45.9) 298 (62.9) 195 (62.7) 0 0 399 (100) 262 (100) 47 (83.9) 31 (83.8) 352 (55.9) 231 (55.0) 122 (62.2) 101 (66.9) 277 (56.5) 161 (52.6) 122 (52.6) 85 (58.6) 128 (56.9) 88 (57.9) 143 (65.6) 87 (56.1)
 Elevated BP, n(%) 85 (90.4) 53 (94.6) 539 (92.0) 365 (91.5) 201 (94.8) 141 (96.6) 429 (90.5) 279 (89.7) 278 (96.9) 189 (96.9) 352 (88.2) 231 (88.2) 0 0 630 (100) 420 (100) 183 (93.4) 142 (94.0) 447 (91.2) 278 (90.8) 212 (91.4) 134 (92.4) 205 (91.1) 139 (91.4) 204 (93.6) 142 (91.6)
 FG ≥ 100 mg/dL, n(%) 55 (58.5) 30 (53.6) 431 (73.5) 275 (68.9) 176 (83.0) 117 (80.1) 314 (66.2) 189 (60.8) 213 (74.2) 145 (74.4) 277 (69.4) 161 (61.5) 43 (76.8) 28 (75.7) 447 (71.0) 278 (66.2) 0 0 490 (100) 306 (100) 124 (53.4) 70 (48.3) 165 (73.3) 102 (67.1) 192 (88.1) 132 (85.2)
LDL-C 138.2 (34.5) 139.1 (33.1) 140.6 (35.7) 135.1 (30) 131.1 (28.9) 133 (29.7) 144.4 (37.5) 136.6 (30.8) 145.7 (34.7) 138.5 (31.2) 136.4 (35.7) 133.2 (29.7) 140.6 (39.7) 131.9 (24.1) 140.2 (35.2) 135.7 (30.9) 148.2 (35.3) 139.7 (29.4) 137.1 (35.2) 133.4 (30.8) 146.7 (35.7) 142 (32.6) 139 (36.2) 134.8 (29.9) 135.6 (34.2) 130 (28)
HDL-C 41.5 (9.7) 42.5 (12.4) 43.3 (10.3) 43.2 (10.8) 46.3 (11.5) 46.8 (12.8) 41.6 (9.3) 41.3 (9.6) 50.3 (10.1) 50.7 (11.2) 37.8 (6.5) 37.6 (6.9) 41.4 (8.1) 37.3 (8.1) 43.2 (10.4) 43.6 (11.1) 41.9 (10.7) 40.4 (10.2) 43.5 (10.1) 44.4 (11.2) 44.2 (11.1) 42.9 (10.6) 43 (9.3) 43.7 (11.2) 41.8 (10.1) 43 (11.3)
non-HDL-C 177.4 (40.9) 179.8 (35.4) 181.1 (40.5) 174.6 (35.8) 156.9 (30.3) 157.9 (31.3) 191.3 (40.1) 183.2 (35) 181.7 (40.7) 173.5 (37.4) 179.9 (40.5) 176.1 (34.6) 182.7 (43.4) 181.6 (35.6) 180.5 (40.3) 174.4 (35.8) 191.8 (40.8) 182.4 (34.5) 176.3 (39.7) 171.5 (35.9) 183 (40.6) 178.5 (38) 181.3 (41.7) 174.8 (33.6) 178.1 (40) 171.9 (36.1)
TGb 171.5 (97.7) 188 (118.6) 186 (99.1) 177 (101.4) 123 (41.4) 121 (42.8) 215 (93.7) 215 (97.7) 162 (85.1) 157.5 (81.9) 200 (106) 199.8 (114.9) 194 (86.7) 217 (141.4) 181.5 (100) 175 (104.2) 201 (105.1) 201 (94.9) 175.8 (99.1) 161.5 (101.4) 167.5 (91.2) 174 (90.2) 183 (109.8) 177.5 (122.3) 196.3 (99.1) 183.5 (109.3)
Total C 218.9 (42.9) 222.3 (39.1) 224.3 (41.1) 218.1 (36.4) 203.2 (33.4) 204.8 (32.5) 232.8 (41.5) 224.9 (37) 232 (40.1) 224.2 (37.7) 217.6 (41.4) 214.2 (35.7) 223.3 (44.1) 218.9 (35) 223.6 (41.2) 218.4 (37) 233.6 (43.3) 222.8 (36.1) 219.7 (40) 216.3 (37) 227 (41.3) 222.4 (41.2) 224.4 (41.9) 218.5 (33.2) 219.9 (41.6) 214.8 (36.1)
Apo B 134.3 (29.2) 137.6 (25.2) 137.3 (30.1) 133.4 (26.5) 121.6 (23.2) 122.7 (22.1) 143.8 (30.3) 138.9 (26.9) 136.5 (29.5) 131.5 (25.9) 137.2 (30.5) 135.2 (26.8) 141.5 (33.2) 138.5 (26.1) 136.5 (29.8) 133.3 (26.5) 144.1 (30.3) 139.8 (25.4) 134 (29.6) 130.7 (26.6) 138.2 (29.5) 138 (27.8) 137.1 (32.3) 132.7 (24.7) 135.5 (28.8) 130.3 (26.5)
Apo AI 140.4 (24.6) 141.5 (27.7) 144.8 (24.3) 144.8 (25.5) 145 (26.3) 146.3 (27.9) 143.7 (23.6) 143.4 (24.6) 157.7 (24.8) 160.7 (26.2) 134.3 (18.8) 132.7 (17.9) 141 (20.1) 136.8 (25.6) 144.4 (24.8) 145 (25.7) 142.1 (26.6) 138.4 (24.7) 144.9 (23.5) 147.2 (25.8) 143.6 (26.5) 142.3 (24.4) 144.7 (22.9) 146.3 (25.4) 143.9 (23.5) 144.5 (27.4)
hs-CRPb 1.8 (2.5) 2(3) 3.3 (4.6) 3.2 (4.7) 3 (5.4) 2.8 (4.4) 3 (4.1) 3.1 (4.2) 2.7 (3.7) 2.4 (3.3) 3.3 (4.8) 3.5 (5.8) 2.3 (2.8) 4.2 (4) 3 (4.6) 2.9 (4.6) 2.9 (3.8) 2.5 (3.1) 3 (4.7) 3.5 (5.3) 2.3 (3.6) 2.3 (3.9) 3 (4) 3.1 (4) 4 (5.3) 3.5 (6)
  1. Apo = apolipoprotein; All A = data for all atorvastatin doses (10/20/40 mg) combined; Apo = apolipoprotein; BMI = body mass index; BP = blood pressure; All E/S = data for all ezetimibe/simvastatin doses (10/20 mg, 10/40 mg) combined; FG = fasting glucose; HDL-C = high density lipoprotein cholesterol; hsCRP = high-sensitivty C-reactive protein, LDL-C = low density lipoprotein cholesterol, n = number of patients in subgroup (numbers vary slightly between parameters), TG = triglycerides; SD = standard devation ametabolic syndrome defined as ≥3 of the following 5 characteristics; abdominal obesity (waist circumference ≥40 inches (males) or ≥35 inches (females)), TG ≥150 mg/dL, low HDL-C (<40 mg/dL (males) or <50 mg/dL (females)), elevated BP (≥130/85 mmHg or on antihypertensive medication or diagnosis of hypertension based on medical history), FG ≥100 mg/dL. brobust SD